Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2145-2152

  Emamaullee, Juliet A ^a,e   Merani, Shaheed ^a   Toso, Christian ^a   Kin, Tatsuya ^b   Al Saif, Faisal ^a   Truong, Wayne ^a   Pawlick, Rena ^b   Davis, Joy ^a   Edgar, Ryan ^a   Lock, Jennifer ^c   Bonner Weir, Susan ^c   Knudsen, Lotte B ^d   Shapiro, A M James ^a  

^a Department of Surgery ^*  (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HARVARD UNIVERSITY   (United States)

^d NOVO NORDISK A S   (Denmark)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIRAGLUTIDE; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; ENGRAFTMENT; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT FAILURE; GRAFT SURVIVAL; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; MINIPIG; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PRIORITY JOURNAL; ANIMAL; ANIMAL DISEASE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; EVALUATION; METABOLIC DISORDER; METABOLISM; METHODOLOGY; PANCREAS ISLET BETA CELL; PHYSIOLOGY; SWINE; TIME; TRANSPLANTATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GRAFT SURVIVAL; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; METABOLIC DISEASES; SWINE; SWINE, MINIATURE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 66449131870     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1116     Document Type: Article

References (32)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV 2000 Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, KnetemanNM, LakeyJR, Shapiro AM 2005 Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-2069
3. Shapiro A, Ricordi C, Hering B, Auchincloss H, Lindblad R, Robertson R, Secchi A, Brendel M, Berney T, Brennan D, Cagliero E, Alejandro R, Ryan E, Diercurio B, P PM, Polonsky K, Reems J, Bretzel R, Bertuzzi F, Froud T, Kandaswamy R, Sutherland D, Eisenbarth G, SegalM, PreiksaitisJ, KorbuttG, Barton F, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey J 2006 International multicenter trial of islet transplantation with the Edmonton Protocol in type 1 diabetes. New Engl J Med 355:12-24
4. BiarnesM, MontolioM, NacherV, RaurellM, SolerJ, MontanyaE 2002 (-Cell death and mass in syngeneically transplanted islets exposed to short- and long- term hyperglycemia. Diabetes 51:66-72
5. Emamaullee JA, Stanton L, Schur C, Shapiro AM 2007 Caspase inhibitor theapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56:1289-1298
6. Alejandro R, Cutfield RG, Shienvold FL, Polonsky KS, Noel J, Olson L, Dillberger J, Miller J, Mintz DH 1986 Natural history of intrahepatic canine islet cell autografts. JClin Invest 78:1339-1348
7. Blondet JJ, Carlson AM, Kobayashi T, Jie T, Bellin M, Hering BJ, Freeman ML, Beilman GJ, Sutherland DE 2007 The role of total pancreatectomy and islet autotransplantation for chronic pancreatitis. Surg Clin North Am 87: 1477-1501
8. Koulmanda M, Smith RN, Qipo A, Weir G, Auchincloss H, Strom TB 2006 Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term anti-CD154-based therapy: nonimmunologic graft failure? Am J Transplant 6:687-696
9. UttenthalLO, GhiglioneM, George SK, Bishop AE, PolakJM, Bloom SR 1985 Molecularformsofglucagon-likepeptide-1 inhumanpancreasandglucagono- mas. J Clin Endocrinol Metab 61:472-479
10. Abdi R, Means TK, Luster AD 2003 Chemokines in islet allograft rejection. Diabetes Metab Res Rev 19:186-190
11. Matsuyama T, Komatsu R, Namba M, Watanabe N, Itoh H, Tarui S 1988 Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insuli- notropic hormone. Diabetes Res Clin Pract 5:281-284
12. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, Di Mario U, Perfetti R 2002 Cultured pancreatic ductal cells undergo cell cycle re-distribution and (-cell-like differentiation in response to glucagon-like peptide-1. JMol Endo- crinol 29:347-360
13. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Th0gersen H, Wilken M, Agers0 H 2000 Potent derivatives of glucagon- like peptide-1 with pharmacokinetic properties suitable for once daily administration. JMed Chem 43:1664-1669
14. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, Cheung AT, Kieffer TJ 2006 Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci USA 103:13468-13473
15. MeraniS, TruongW, EmamaulleeJA, TosoC, KnudsenLB, ShapiroAM2008 Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 149:4322-4328
16. Ghofaili KA, FungM, Ao Z, Meloche M, Shapiro RJ, WarnockGL, Elahi D, Meneilly GS, Thompson DM 2007 Effect of exenatide on (-cell function after islet transplantation in type 1 diabetes. Transplantation 83:24-28
17. Sharma A, Sorenby A, Wernerson A, Efendic S, Kumagai-Braesch M, Tibell A 2006 Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia 49:1247-1253
18. Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, Lake SP, London NJ, Socci C, Alejandro R, Zeng Y, Scharp D, Viviani G, Falqui L, Tzakis A, Bretzel R, Federlin K, Pozza G, James RFL, Rajotte R, DiCarloV, MorrisPJ, SutherlandDER, StarzlT, MintzDH, LacyP1990 Islet isolation assessment in man and large animals. Acta Diabetol Lat 27:185-195
19. Barnett MJ, McGhee-Wilson D, Shapiro AM, Lakey JR 2004 Variation in human islet viability based on different membrane integrity stains. Cell Transplant 13:481-488
20. Lake SP, Bassett PD, Larkins A, Revell J, Walczak K, Chamberlain J, Rumford GM, London NJ, Veitch PS, Bell PR 1989 Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 38(Suppl 1):143-145
21. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, Elliott JF 2005 XIAP overexpression in human islets prevents early posttrans- plant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 54:2541-2548
22. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP 1998 Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324-330
23. Toso C, Brandhorst D, Oberholzer J, Triponez F, Buhler L, Morel P 2000 Isolation of adult porcine islets of Langerhans. Cell Transplant 9:297-305
24. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS 2005 The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits (-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577-584
25. Raun K, von Voss P, Knudsen LB 2007 Liraglutide, a once-daily human glu- cagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 15:1710-1716
26. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, DeaconCF, KnudsenLB2002NN2211: along-actingglucagon-likepeptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur JPharmacol 451:217-225
27. Laybutt DR, Hawkins YC, Lock J, Lebet J, Sharma A, Bonner-Weir S, Weir GC 2007 Influence of diabetes on the loss of (-cell differentiation after islet transplantation in rats. Diabetologia 50:2117-2125
28. Ritzel RA, Meier JJ, LinCY, Veldhuis JD, Butler PC 2007 Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56:65-71
29. WestermarkP, AnderssonA, WestermarkGT2005 Is aggregated IAPP acause of (-cell failure in transplanted human pancre aticislets? Curr Diab Rep 5: 184-188
30. Lukinius A, Korsgren O, Grimelius L, Wilander E 1997 Expression of islet amyloidpolypeptideinfetalandadultporcineandhumanpancreaticisletcells. Endocrinology 138:5319-5325
31. Jaikaran ET, Clark A2001 Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537:179-203
32. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P 1988 Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic β-cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130:1-8